拜玛林制药 BMRN 深 沪
等待开盘 11-04 09:30:00 美东时间
52.85
-0.720
-1.34%
华盛通- 最 高54.2499
- 今 开53.03
- 成交量 268.58万股
- 最 低 52.06
- 昨 收 53.57
- 总市值 101.47亿
- 52周最高 73.51
- 市盈率 静 23.94
- 换手率 1.40%
- 52周最低 51.00
- 委 比 32.56%
- 总股本 1.92亿
- 历史最高 151.75
- 量 比 0.59
- 振 幅 4.09%
- 历史最低 23.735
- 每 手 1
- 风险率 5.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
今天 10:31
美股大行评级 | 上调！苹果、亚马逊、Amkor Tech、Cadence、Confluent、卡特、通用动力等获多家上调目标价
今日重点评级关注：HC Wainwright & Co.：维持PepGen"买入"评级，目标价从12美元升至18美元；Piper Sandler：维持Prothena Corp"超配"评级，目标价从15美元升至36美元
10-29 09:25
BioMarin为其药物VOXZOGO设定2025年9-9.35亿美元营收目标
美股周二早盘，生物技术企业BioMarin Pharmaceutical （BMRN）股价上涨4.4%，此前该公司为其药物VOXZOGO设定2025年9-...
10-28 23:00
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $104 to $98.
10-28 19:15
电话会总结 ｜ BioMarin(BMRN)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据BioMarin 2025年第三季度业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - 2025年前三季度总营收同比增长11% - Voxzogo产品前三季度营收同比增长24%，第三季度同比增长15% - Palynziq产品前三季度营收同比增长超过20% - 酶疗法业务单元前三季度营收同比增长8%，过去12个月营收超过20亿美元 - 第三季度酶疗法营收环比下降（由于第二季度Naglazyme和Vimizim的大额订单），同比基本持平 **盈利能力：** - 第三季度经营现金流达到3.69亿美元 - 前三季度经营现
10-28 12:02
BioMarin seeks to divest hemophilia A gene therapy Roctavian
BioMarin Pharmaceutical (NASDAQ:BMRN) said it will look to divest Roctavian (valoctocogene roxaparvovec), a one-time gene therapy for hemophilia A to focus more on its core treatments. Offloading Roct...
10-28 05:13
BioMarin Pharmaceutical Lowers FY2025 Adj EPS Guidance from $4.40-$4.55 to $3.50-$3.60 vs $3.25 Est; Raises FY2025 Sales Guidance from $3.125B-$3.200B to $3.150B-$3.200B vs $3.171B Est
BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2025 Adj EPS guidance from $4.40-$4.55 to $3.50-$3.60 vs $3.25 analyst estimate. Raises FY2025 sales outlook from $3.125 billion-$3.200 billion to $3.150 billion-$3.200
10-28 04:07
Earnings Scheduled For October 27, 2025
Companies Reporting Before The Bell • Keurig Dr Pepper (NASDAQ:KDP) is projecte...
10-27 16:32
What to Expect from Biomarin Pharmaceutical's Earnings
Biomarin Pharmaceutical (NASDAQ:BMRN) is preparing to release its quarterly ear...
10-24 23:01
Biomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica reported Q1 FY2026 financial results with net sales of $1.4 million, a decrease compared to $1.8 million in Q1 FY2025, due to reduced retail activity and international order timing. Despite lower sales, gross margin improved to 31% from 16% due to higher-margin product mix. Operating expenses declined to $1.5 million from $1.7 million, reflecting cost reduction efforts. The company achieved a net profit of approximately $2,000, compared...
10-15 13:27
